Business
AI programme yields novel RSV drug targets
AI programme yields novel RSV drug targets.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n \n \n \n Poolbeg Pharma Plc\n \n \n \n \n \n \n \n Artificial intelligence programme yields multiple novel RSV drug targets\n \n \n \n \n First time AI has been used to identify disease targets in RSV\n \n \n \n \n \n \n 8 November 2022 -\n \n \n Poolbeg Pharma\n \n \n (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence ('AI') Programme with partner\n \n \n OneThree Biotech\n \n \n , Inc. through the discovery of novel drug targets for the treatment of Respiratory Syncytial Virus ('RSV').\n \n \n \n \n \n Following the completion of the build and optimisation of a tailored AI model in\n \n \n June 2022\n \n \n , the OneThree team, using its clinically validated AI platform, have identified novel drug targets using Poolbeg's unique RSV human challenge trial data. The identification of these novel drug targets now allows the final stage of the programme to commence which will involve the identification of small molecule inhibitors to effectively treat RSV infections. The team are particularly excited as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Prioritisation of compounds with existing Phase I data aligns with Poolbeg's capital light model as these compounds will have extensive nonclinical and clinical data allowing smooth transition to early human efficacy trials.\n \n \n \n \n \n The final stage of the research plan will utilise OneThree's proprietary ATLANTIS AI platform to identify the drugs that are most likely to be efficacious against the identified disease targets with clean safety profiles in RSV patients. Selection of drugs is traditionally a long and extensive process, however, by using an existing AI model this process can be completed in weeks. Results of this stage are expected before year end 2022.\n \n \n \n \n \n Traditional drug design is focused on identifying a molecule that can bind with a specific target within a cell. Poolbeg's approach, utilising OneThree Biotech's advanced AI models, allows for the complex disease signature underlying each drug target to be considered during drug selection. This allows the comple...